CDKN2B and acute myeloid leukemia: Cell surface lectin CD93, predominantly expressed on endothelial cells, selectively marks and essentially maintains LSCs (leukemia stem cells) through silencing of CDKN2B (cyclin-dependent kinase inhibitor 2B), a significant cell cycle inhibitor, which makes CD93 a primary target to acute myeloid leukemia (AML) [58].